Antisense Therapeutics Limited (AU:PER) has released an update.
Percheron Therapeutics Limited reported a successful quarter with the completion of Phase IIb trial recruitment for ATL1102 in Duchenne muscular dystrophy, receiving a provisional international non-proprietary name ‘avicursen’ for the drug, and securing a key US patent. Preliminary results from the ATL1102 nine-month animal study indicated no new toxicities, supporting its ongoing development. Additionally, the firm bolstered its executive team with two key appointments, enhancing its management and business strategy.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
